168 related articles for article (PubMed ID: 29025359)
21. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Shan W; Yuan J; Hu Z; Jiang J; Wang Y; Loo N; Fan L; Tang Z; Zhang T; Xu M; Pan Y; Lu J; Long M; Tanyi JL; Montone KT; Fan Y; Hu X; Zhang Y; Zhang L
Cell Rep; 2020 Jul; 32(2):107884. PubMed ID: 32668240
[TBL] [Abstract][Full Text] [Related]
22. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
23. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
24. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
25. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
26. THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors.
Shyamsunder P; Sridharan SP; Madan V; Dakle P; Zeya C; Kanojia D; Chng WJ; Ong ST; Koeffler HP
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163134
[TBL] [Abstract][Full Text] [Related]
27. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
[TBL] [Abstract][Full Text] [Related]
28. Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Tentori L; Leonetti C; Muzi A; Dorio AS; Porru M; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Int J Oncol; 2013 Jul; 43(1):210-8. PubMed ID: 23653048
[TBL] [Abstract][Full Text] [Related]
29. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
Yan Y; Spieker RS; Kim M; Stoeger SM; Cowan KH
Oncogene; 2005 May; 24(20):3285-96. PubMed ID: 15735702
[TBL] [Abstract][Full Text] [Related]
30. The POLD1
Job A; Tatura M; Schäfer C; Lutz V; Schneider H; Lankat-Buttgereit B; Zielinski A; Borgmann K; Bauer C; Gress TM; Buchholz M; Gallmeier E
Sci Rep; 2020 Nov; 10(1):18924. PubMed ID: 33144657
[TBL] [Abstract][Full Text] [Related]
31. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
32. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Vrábel D; Svoboda M; Navrátil J; Kohoutek J
Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
[TBL] [Abstract][Full Text] [Related]
33. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
[TBL] [Abstract][Full Text] [Related]
34. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
[TBL] [Abstract][Full Text] [Related]
35. Chk1 loss creates replication barriers that compromise cell survival independently of excess origin firing.
González Besteiro MA; Calzetta NL; Loureiro SM; Habif M; Bétous R; Pillaire MJ; Maffia A; Sabbioneda S; Hoffmann JS; Gottifredi V
EMBO J; 2019 Aug; 38(16):e101284. PubMed ID: 31294866
[TBL] [Abstract][Full Text] [Related]
36. Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy.
Hopkins JL; Zou L
Cancer Cell; 2019 Nov; 36(5):461-463. PubMed ID: 31715127
[TBL] [Abstract][Full Text] [Related]
37. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
38. Drug discovery targeting Chk1 and Chk2 kinases.
Zhou BB; Sausville EA
Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
[TBL] [Abstract][Full Text] [Related]
39. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.
Santoro A; Pisanti S; Grimaldi C; Izzo AA; Borrelli F; Proto MC; Malfitano AM; Gazzerro P; Laezza C; Bifulco M
Int J Cancer; 2009 Sep; 125(5):996-1003. PubMed ID: 19479993
[TBL] [Abstract][Full Text] [Related]
40. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
